Tob1 induces apoptosis and inhibits proliferation, migration and invasion of gastric cancer cells by activating Smad4 and inhibiting β-catenin signaling

Transducer of ErbB-2.1 (Tob1), a tumor suppressor protein, is inactivated in a variety of cancers including stomach cancer. However, the role of Tob1 in gastric carcinogenesis remains elusive. The present study aimed to investigate whether Tob1 could inhibit gastric cancer progression in vitro, and to elucidate its underlying molecular mechanisms. We found differential expression of Tob1 in human gastric cancer (MKN28, AGS and MKN1) cells. The overexpression of Tob1 induced apoptosis in MKN28 and AGS cells, which was associated with sub-G1 arrest, activation of caspase-3, induction of Bax, inhibition of Bcl-2 and cleavage of poly (ADP-ribose) polymerase (PARP). In addition, Tob1 inhibited proliferation, migration and invasion, which were reversed in MKN1 and AGS cells transfected with Tob1 siRNA. Overexpression of Tob1 in MKN28 and AGS cells induced the expression of Smad4, leading to the increased expression and the promoter activity of p15, which was diminished by silencing of Tob1 using specific siRNA. Tob1 decreased the phosphorylation of Akt and glycogen synthase kinase-3β (GSK3β) in MKN28 and AGS cells, resulting in the reduced protein expression and the transcriptional activity of β-catenin, which in turn decreased the expression of cyclin D1, cyclin-dependent kinase-4 (CDK4), urokinase plasminogen activator receptor (uPAR) and peroxisome proliferator and activator receptor-δ (PPARδ). Conversely, silencing of Tob1 induced the phosphorylation of Akt and GSK-3β, and increased the expression of β-catenin and its target genes. Collectively, our study demonstrates that the overexpression of Tob1 inhibits gastric cancer progression by activating Smad4- and inhibiting β-catenin-mediated signaling pathways.

[1]  B. Nielsen,et al.  Urokinase plasminogen activator receptor is expressed in invasive cells in gastric carcinomas from high‐ and low‐risk countries , 2010, International journal of cancer.

[2]  W. Shen,et al.  Inhibition of pancreatic carcinoma cell growth in vitro by DPC4 gene transfection. , 2008, World journal of gastroenterology.

[3]  Young Deug Kim,et al.  The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo , 2012, International journal of cancer.

[4]  Y. Morita,et al.  Expression of urokinase‐type plasminogen activator receptor and plasminogen activator inhibitor‐1 in gastric cancer , 1998, Journal of gastroenterology and hepatology.

[5]  G. Bellis,et al.  Transmembrane Motility Assay of Transiently Transfected Cell s by Fluorescent Cel l Counting and Luciferas e , 2000 .

[6]  S. Matsuda,et al.  Tumor growth suppression by adenovirus-mediated introduction of a cell-growth-suppressing gene tob in a pancreatic cancer model. , 2009, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[7]  D. Guardavaccaro,et al.  Arrest of G1-S Progression by the p53-Inducible Gene PC3 Is Rb Dependent and Relies on the Inhibition of Cyclin D1 Transcription , 2000, Molecular and Cellular Biology.

[8]  Y. Nakamura,et al.  Tob, a novel protein that interacts with p185erbB2, is associated with anti-proliferative activity. , 1996, Oncogene.

[9]  O. Cummings,et al.  Inactivation of Smad4 in gastric carcinomas. , 1997, Cancer research.

[10]  N. Shinomiya,et al.  Urokinase type plasminogen activator and its receptor regulate the invasive potential of gastric cancer cell lines. , 2000, International journal of oncology.

[11]  Tao Zhang,et al.  TOB suppresses breast cancer tumorigenesis , 2009, International journal of cancer.

[12]  G. Bommer,et al.  Wnt/Beta-Catenin/Tcf Signaling: A Critical Pathway in Gastrointestinal Tumorigenesis , 2002, Digestion.

[13]  M. Ffrench,et al.  BTG1, a member of a new family of antiproliferative genes. , 1992, The EMBO journal.

[14]  Lin Zhao,et al.  Suppression of human lung cancer cell proliferation and metastasis in vitro by the transducer of ErbB-2.1 (TOB1) , 2011, Acta Pharmacologica Sinica.

[15]  Naoto Hirano,et al.  Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells , 2001, Nature Immunology.

[16]  D. Theodorescu,et al.  Transmembrane motility assay of transiently transfected cells by fluorescent cell counting and luciferase measurement. , 2000, BioTechniques.

[17]  M. Hirai,et al.  Tob2, a novel anti-proliferative Tob/BTG1 family member, associates with a component of the CCR4 transcriptional regulatory complex capable of binding cyclin-dependent kinases , 1999, Oncogene.

[18]  Guanlin Wang,et al.  Secretory leukocyte protease inhibitor is associated with MMP-2 and MMP-9 to promote migration and invasion in SNU638 gastric cancer cells. , 2011, International journal of molecular medicine.

[19]  S. Fan,et al.  Adenovirus-mediated expression of Tob1 sensitizes breast cancer cells to ionizing radiation1 , 2007, Acta Pharmacologica Sinica.

[20]  R. Glazer,et al.  Induction of Metastatic Gastric Cancer by Peroxisome Proliferator-Activated Receptorδ Activation , 2010, PPAR research.

[21]  C. Sherr,et al.  Principles of Tumor Suppression , 2004, Cell.

[22]  A. Ristimäki,et al.  Gastric Cancer: Basic Aspects , 2011, Helicobacter.

[23]  Sheng-Cai Lin,et al.  Tob1 controls dorsal development of zebrafish embryos by antagonizing maternal beta-catenin transcriptional activity. , 2006, Developmental cell.

[24]  C. Elmets,et al.  Pharmacological activation of p53 in cancer cells. , 2011, Current pharmaceutical design.

[25]  S. Dedhar,et al.  Signaling through beta-catenin and Lef/Tcf. , 1999, Cellular and molecular life sciences : CMLS.

[26]  S. Dedhar,et al.  Tumor Suppressor Pten Inhibits Nuclear Accumulation of β-Catenin and T Cell/Lymphoid Enhancer Factor 1–Mediated Transcriptional Activation , 2001, The Journal of cell biology.

[27]  W. Schmiegel,et al.  DPC4/SMAD4 mediated tumor suppression of colon carcinoma cells is associated with reduced urokinase expression , 1999, Oncogene.

[28]  Aimin Li,et al.  Smad4 restoration leads to a suppression of Wnt/beta-catenin signaling activity and migration capacity in human colon carcinoma cells. , 2009, Biochemical and biophysical research communications.

[29]  T. Noda,et al.  Mice lacking a transcriptional corepressor Tob are predisposed to cancer. , 2003, Genes & development.

[30]  Li-hui Wang,et al.  Inactivation of SMAD4 Tumor Suppressor Gene During Gastric Carcinoma Progression , 2007, Clinical Cancer Research.

[31]  A. Miyauchi,et al.  Phosphorylation and inactivation of Tob contributes to the progression of papillary carcinoma of the thyroid. , 2005, Cancer letters.

[32]  J. Bai,et al.  Identification of novel subregions of LOH in gastric cancer and analysis of the HIC1 and TOB1 tumor suppressor genes in these subregions , 2011, Molecules and cells.

[33]  Taesung Park,et al.  Identification of Novel Reference Genes Using Multiplatform Expression Data and Their Validation for Quantitative Gene Expression Analysis , 2009, PloS one.